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Abstract
The use of selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression
during pregnancy is suggested to increase the incidence of craniofacial abnormalities
including craniosynostosis. Little is known about this mechanism, however based on previ-
ous data we propose a mechanism that affects cell cycle. Excessive proliferation, and
reduction in apoptosis may lead to hyperplasia within the suture that may allow for differenti-
ation, bony infiltration, and fusion. Here we utilized in vivo and in vitro analysis to investigate
this proposed phenomenon. For in vivo analysis we used C57BL–6 wild-type breeders
treated with a clinical dose of citalopram during the third trimester of pregnancy to produce
litters exposed to the SSRI citalopram in utero. At post-natal day 15 sutures were harvested
from resulting pups and subjected to histomorphometric analysis for proliferation (PCNA)
and apoptosis (TUNEL). For in vitro studies, we used mouse calvarial pre-osteoblast cells
(MC3T3-E1) to assess proliferation (MTS), apoptosis (Caspase 3/7-activity), and gene
expression after exposure to titrated doses of citalopram. In vivo analysis for PCNA sug-
gested segregation of effect by location, with the sagittal suture, showing a statistically sig-
nificant increase in proliferative response. The coronal suture was not similarly affected,
however there was a decrease in apoptotic activity at the dural edge as compared to the
periosteal edge. No differences in apoptosis by suture or area due to SSRI exposure were
observed. In vitro results suggest citalopram exposure increased proliferation and prolifer-
ative gene expression, and decreased apoptosis of the MC3T3-E1 cells. Decreased apo-
ptosis was not confirmed in vivo however, an increase in proliferation without a concomitant
increase in apoptosis is still defined as hyperplasia. Thus prenatal SSRI exposure may
exert a negative effect on post-natal growth through a hyperplasia effect at the cranial
growth sites perhaps leading to clinically significant craniofacial abnormalities.
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Introduction
Research has suggested selective serotonin reuptake inhibitors (SSRIs) used to treat depression
in pregnant women may increase the risk of birth defects, specifically those of the craniofacial
skeleton [1–7]. These data remain controversial [8–14] and there is lack of agreement concern-
ing safety, trimester of use, drug specificity and dose, causation and mechanism of effect. Still,
life time risk of major depression among women approaches 25% and is highest during their
childbearing years, resulting in high use of antidepressants during pregnancy. In the United
States, it is estimated that 7% to 13% of pregnant women have consumed antidepressants and
numbers are rising as are concerns for the health outcomes of newborns [15, 16]. Along these
lines the once heavily prescribed SSRI, paroxetine (Paxil) has been re-classified for pregnancy
risk from class C to class D, indicating its potential risks to the developing fetus, specifically for
cardiac anomalies [17].
There are now clinical reports linking SSRI use and the developmental disruption of cranial
vault size, shape and possible association with craniosynostosis [4, 5]. Such results have previ-
ously been observed in preclinical models [18–20]. Craniosynostosis is defined as the premature
fusion of one or more of the fibrous joints between the major bones of the skull known as cranial
sutures [21, 22]. Worldwide incidence of craniosynostosis is 1 in every 2100 to 2500 live births
with commonly reported comorbidities of mental retardation, deafness, optic nerve compression,
altered cranial volume, midface growth discrepancies and increased intracranial pressure. The
etiology of craniosynostosis is poorly understood but incidences can occur due to targeted gene
mutations (FGF, Twist, MSX2) or environmental factors but in the majority of cases causation is
unknown [21–23]. Our group has previously investigated the effects of one SSRI, citalopram
(Celexa) on the developing murine craniofacial skeleton. Utilizing in utero exposures to a wild-
type model we confirmed in vivo effects in the offspring similar to that previously reported in the
aforementioned preclinical and clinical studies including altered cranial vault shape, decreased
cranial growth, and craniofacial anomalies including suture synostosis [24].
There are several hypotheses for the pathogenesis of craniosynostosis focused on cellular
imbalances including aplasia (suture agenesis), dysplasia (change in cell phenotype, essentially
differentiation) and hyperplasia due to an imbalance between the processes of cell proliferation
and apoptosis of the cells that comprise the suture mesenchyme [21, 25–31]. In a normal devel-
oping skull, a balance exists between cell proliferation and apoptosis, whereas, in the craniosy-
nostotic skull, cell proliferation is believed to be a dominant and disruptive force. This
imbalance likely leads to later differentiation of cells in the suture allowing for bony infiltration
and fusion. In our previous research using murine calvarial cells we observed increased mark-
ers of osteoblastogenesis as well as alteration in overall cell proliferation after citalopram expo-
sure [24]. Though poorly understood, there is now evidence to suggest that serotonin (SSRIs
use results in increased production of brain serotonin) may play a significant role in early cra-
niofacial development, including brain development, neural crest cell migration and develop-
ment of the structures of the head and face as well as normal bone physiology [2, 5, 32–34].
Given the frequency of SSRI use during pregnancy it is imperative that any potential terato-
genic effects be subject to continued investigation for these drugs. Based on previous data, here
we sought to test the hypothesis that exposure to SSRIs would alter the proliferation and apo-
ptosis of perisutural cells at the cellular and transcription levels.
Materials and Methods
SSRI Treated Perinates
We previously reported on the effects of in utero citalopram exposure on postnatal skull mor-
phology [24]. To investigate in vivo effects of SSRI treatment on proliferation and apoptosis at
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the cranial growth sites, representative samples were utilized here from our sample of exposed
(n = 24) and unexposed (n = 26) 15 day old C57BL6 mice. As previously described, individually
housed pregnant C57BL6 dams (Jackson Laboratories, Bar Harbor, ME) were administered a
dose of approximately 500 micrograms per day in drinking water of citalopram from embry-
onic day (E)13 to E20 (roughly the third trimester). Dosage was identified as midrange for pre-
clinical studies in murine models and were replaced as needed to provide ad labium access
[35–37]. Resulting offspring were allowed to grow to postnatal day 15 when they were sacri-
ficed via carbon dioxide asphyxiation and subsequent cervical dislocation and decapitation.
Calvaria were harvested then isolated for use in these studies. The Animal Use Protocol was
reviewed and approved by the Georgia Regents University Institutional Animal Care and Use
Committee, 2012–0498. All breeding procedures were carried out in an Association for Assess-
ment and Accreditation of Laboratory Animal Care International accredited facility where all
husbandry and related services are provided by the Division of Laboratory Animal Resources.
Histomorphometrics
Randomly selected calvarial samples per group (control (unexposed) and exposed n = 3) were
fixed in 3.7% formaldehyde for 48 hours then were decalcified in 0.25M EDTA at pH7.4 for
10 days with changes of the EDTA every 3 days. The sutures were isolated from the top of the cal-
varia and were washed, dehydrated in a graded series of ethyl alcohol (70–100%), cleared in
xylene, and embedded in paraffin. Prior to embedding, samples were cut in half posterior and
parallel to the coronal suture and the front half of the calvaria was again bisected along the sagit-
tal suture to allow for embedding in an orientation that allowed for cutting through both sutures
at 8μm using a rotary microtome prior to mounting on Super Frost Plus glass slides for histology.
Serial sections were subjected to immunohistochemistry for Proliferating Cell Nuclear Anti-
gen (PCNA), a marker associated with cell proliferation. Briefly, sections were depraffinized
and rehydrated to water. Endogenous peroxidase was blocked with 3% hydrogen peroxide in
methanol, and then 1% Goat Serum was used to block non-specific binding. Sections were then
incubated with PCNA primary antibody (AbCam, Cambridge, MA, USA, ab18197) diluted 1
to 3000 in Goat Serum for 1 hour at room temperature. After three washes with Phosphate-
Buffered Saline (PBS) sections were incubated with Goat Anti-Rabbit Secondary Antibody con-
jugated for HRP (AbCam, ab6721) for 1 hour at room temperature and were subsequently
washed again with PBS three times. Finally, sections were exposed to 3,3’-diaminobenzidine
(DAB) (Vectror Laboratories, Bulingame, CA, USA) for 3 minutes, the reaction was stopped
with water, and the sections were dehydrated, cleared, and mounted with permount (Fisher
Scientific, Waltham, MA, USA). Sections serial to those stained with PCNA served as second-
ary antibody only controls and were counterstained for 30 seconds with Harris Hematoxylin
diluted 1:10 in water after the DAB reaction was stopped. Slides were then imaged with a VWR
microscope equipped with a moticam digital camera and imaging software (VWR, Radnor,
PA, USA).
Terminal deoxynucleotidyl tranferase dUTP nick end labeling (TUNEL), a method for
detecting DNA fragmentation, was performed according to the manufacturer protocol (Roche,
Indianapolis, IN, USA, 11 684 795 910). Briefly, sections were deparaffinized and rehydrated,
and then subjected to epitope retrieval via a 1 minute microwave incubation with 0.1mM
Sodium Citrate Buffer (10mM Sodium Citrate 0.5% Tween 20 pH 6.0). After cooling in water
and washing in PBS the slides were incubated in Tris-HCl buffer (0.1M Tris HCl ph 7.5 3%
Bovine Serum Albumin 20% Fetal Bovine Serum), then washed tree times in PBS and incu-
bated with activated TUNEL reaction staining solution for 1 hour at 37 degrees in the dark.
After incubation, the slides were washed with PBS and mounted using Vectashield
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4',6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Bulingame, CA, USA) mounting
media. Slides were then imaged with an Olympus BX61 microscope equipped with an Olympus
DP72 8-bit RGB camera and Cellsens imaging software (Olympus, Waltham, MA, USA).
Image analysis was performed using Image J Software [38]. Average background threshold
was determined by selecting 3 areas per control (secondary only, or inactive TUNEL reaction
staining solution) image and determining the threshold at which no pixels were able to be iden-
tified. This threshold was then applied to all images taken of either staining technique. The
sutural area was isolated as well as the osteogenic front for three sections (at least 30μm apart)
for each suture for each group (control (unexposed) and exposed n = 3). For PCNA total cell
count was identified via hematoxylin stain in a section serial to the section stained for PCNA.
Cells positive for PCNA were then identified as a percent of the total cells counted. For localiza-
tion of staining (periosteal, midsutural, dural and osteogenic front) the suture was measured
from dura to periosteum and that length was divided by 3 to determine the size of the localized
areas. For TUNEL staining total cell count was identified via a DAPI nuclear counterstain.
Photos were taken of the same section using different filters to allow for the FITC positive
TUNEL staining to be compared to the total cell count from the DAPI staining. Merged images
of the different excitation channels were also created.
Cell Culture and Characterization
Previous data has demonstrated a significant effect of the SSRI citalopram on osteogenic
response and relevant gene expression on mouse calvarial pre-osteoblasts [24]. The MC3T3-E1
murine calvaria osteoprogenitor cells are a stock immortalized cell line (American Type Cul-
ture Collection (ATCC), Manassas, VA, USA). Here we use those same cells to determine
direct changes to proliferation or apoptosis after citalopram exposure. Cells were cultured in
alpha minimum Eagles medium (αMEM, Lonza, Allendale, NJ, USA) supplemented with 1%
penicillin/streptomycin (pen/strep, Life Technologies, Grand Island, NY, USA), 10% fetal
bovine serum (FBS, Atlanta Biologicals, Flowery Branch, GA) and Amphotericin B (Lonza).
For control data, cells were cultured for 3 or 7 days with standard alpha proliferation media.
For SSRI treatments, media was supplemented with citalopram eluted to serially diluted doses
between 10−4 mol through 10−10 mol to achieve a dose response curve.
The effects of SSRI exposures on metabolic markers of cell proliferation and apoptosis were
assessed via MTS [39] and Apo-ONE Homogeneous Caspase–3/7 (Promega, Madison, WI,
USA) per manufacturer instructions. Cells were seeded in triplicate into 96-well plates at a den-
sity of approximately 4,000 cells/well and treated for 3 or 7 days. For MTS assay after 3 or 7
days of treatment, cells were incubated for one hour with 20μl/well of CellTiter96 Aqueous
One solution. The absorbance at 490nm was recorded with a 96-well plate reader (Biotek, Syn-
ergy H1 Mono, Winooski, VT, USA). Our sample size was n = 3 per condition. For Caspase 3/
7 apoptosis assay after 3 or 7 days of treatment, cells were incubated with 100 μl/well substrate/
buffer solution (1:100). Contents were mixed for 30 seconds at 300 rpm and incubated at room
temperature for one hour. Fluorescence was measured using a 96-well plate reader (Biotek)
with excitation at 485 and emission at 530 nm. Our sample size was n = 3 per condition.
Quantitative Real Time Polymerase Chain Reaction (qrt-PCR)
Quantitative real time polymerase chain reactions (qrt-PCRs) were run using a one-step kit for
cDNA synthesis and gene expression (TaqMan1 RNA-to-Ct™ 1-Step Kit, Life Technologies,
Thermo-Fisher Scientific, Walltham, MA, USA) following manufacturer instructions. A master
mix was made from nuclease free water, rt-mix, enzyme mix and commercially prepared
probe/primer sets (Taqman Gene Expression Assays, Table 1). A total of 50ug of RNA from
SSRI Exposure Promotes Calvarial Cell Hyperplasia
PLOS ONE | DOI:10.1371/journal.pone.0139719 October 2, 2015 4 / 14
murine calvaria osteoprogenitor cells was added to the master mix for each reaction (run in
duplicate) for each gene product for each condition time (3 or 7 day) by treatment (media only
control or media supplemented with 10−4 mol/L citalopram). Data were normalized to 18S ribo-
somal RNA expression by ΔCT. Quantitative data were compared for gene expression change
due to treatment by ΔΔCTmethodology. Genes of interest were both markers associated with
osteoblast progenitor proliferation, Ki67, Ccnd1, Jun and apoptosis Bax, Casp3, and Bcl2.
Statistical Analysis
For ex-vivo PCNA and TUNEL analyses, data were utilized as a proportion of cells expressing
the marker over the total number of cells per area of interest (periosteal, midsutural, dural and
osteogenic front). Data was analyzed by three and two-way analysis of variance (ANOVA) to
determine differences in PCNA and TUNEL activity due to exposure (none or citalopram),
suture (differences between coronal or sagittal sutures), and area of the suture. All data was
subjected to tests for normality (Shapiro-Wilk) and homogeneity of variances (Browne-For-
sythe). Post-hoc analyses of intergroup differences were conducted using Bonferonni method-
ology. Differences were considered statistically significant if p<0.05.
For proliferation and apoptosis cellular assays, raw values were used to conduct two ANOVAs
for treatment (untreated control and citalopram doses between 10−4 mol through 10−10 mol/liter)
by assay time point, 3 or 7 days. All data was subjected to tests for normality (Shapiro-Wilk) and
homogeneity of variances (Browne-Forsythe). Post-hoc analyses of intergroup differences were
conducted using Bonferonni methodology. Differences were considered statistically significant if
p<0.05. All statistical analyses were conducted using SPSS 22 (IBM, Armonk, NY, USA).
For qrt-PCR analyses were conducted following manufacturer description and published
methodology plotting mean fold change and upper and low bounds confidence interval (+/-
one standard deviation) (Applied Biosystems, Life Technologies). A fold change simply repre-
sents the percent increase or decrease in the amount of gene expression for a target subject to
qrt-PCR and ΔΔCT methodology. A fold change that does not cross 1 or -1 can be considered
to have some relevant biological alteration in expression level. In addition, we have followed
statistical analysis as previously published to determine statistical differences for gene expres-
sion after citalopram treatment for target of interest by time of exposure [40]. Differences were
considered statistically different if p0.05.
Results
Markers of Proliferation
Fig 1A, 1B, 1D and 1E demonstrates representative samples of Proliferating Cell Nuclear Anti-
gen (PCNA, a marker of proliferation) staining for coronal and sagittal sutures from postnatal
Table 1. Quantitative qRT-PCR TaqMan Probe/Primer Set Data.
Gene Symbol Gene Name Primer Sequence Context Sequence
Mki67 Marker of Proliferation Ki67 Mm01278617_m1 GACAATCATCAAGGAACGGCCCCAG
Ccnd1 Cyclin D1 Mm00432359_m1 CTCTGTGCCACAGATGTGAAGTTCA
Jun Jun Proto-oncogene Mm00495062_s1 GAACTGGGGAGGAGGGCTCAGGGGG
Bax BCL Associated X Protein Mm00432051_m1 CAAGACCAGGGTGGCTGGGAAGGCC
Casp3 Caspase 3 Mm01195085_m1 TCTACAGCACCTGGTTACTATTCCT
Bcl2 B-cell CLL/lymphoma 2 Mm00477631_m1 CGGAGGCTGGGATGCCTTTGTGGAA
18S 18S ribosomal RNA Mm03928990_g1 TACTTGGATAACTGTGGTAATTCTA
doi:10.1371/journal.pone.0139719.t001
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day 15 animals either unexposed (control) or exposed in utero to the SSRI citalopram. Qualita-
tive assessment suggest increased PCNA staining for SSRI exposed animal sutures. Quantita-
tive analysis was conducted for percent cells PCNA positive as a function of total cells present.
A three-way analysis of variance was conducted to determine if the relationship for exposure
(control or citalopram) by area of suture was the same for coronal and sagittal suture samples.
Assumptions of normality and homogeneity of variance were met. Results indicated a signifi-
cant difference for suture by exposure interaction term, F = 7.215, p = 0.011 with PCNA
increasing with citalopram exposure for the sagittal suture and the coronal not changing or
slightly decreasing. Two-way analyses of variance were conducted for the coronal and sagittal
sutures. The results for the coronal suture are illustrated in Fig 1C. Data suggest slight decreases
in markers of proliferation in the periosteal and midsutural areas analyzed. The assumption of
homogeneity of variance was met. Statistical analyses revealed no significant differences for
exposure by area, or exposure and area main effects, p>0.05. The results for the sagittal suture
are illustrated in Fig 1F. Data suggest increases in all suture areas analyzed. Statistical analyses
revealed a significant difference by exposure, F = 6.203, p = 0.024, with the SSRI exposed
sutures demonstrating greater PCNA positivity (47.94+/-35.47> 21.38+/-16.15).
Fig 2A demonstrates results for analysis of proliferation via MTS assay for MC3T3-E1 cells
after citalopram treatment in culture for 3 and 7 days. Qualitative assessment suggests an
increase in MTS activity for all treated groups compared to untreated baseline control. A two
way analysis of variance was conducted for days in culture by citalopram dose for MTS activity.
Assumptions of normality and homogeneity of variance were met. Results suggest significant
differences in MTS activity by day, F = 105.062, p<0.001, with greater activity observed after
7 days (0.62 +/-0.06) compared to 3 days (0.48 +/-0.07). There was also a significant effect by
Fig 1. Histological markers of proliferation in control and citalopram exposedmouse cranial sutures.
A & B. Coronal sutures from control (A) and citalopram exposed (B) 15 day old C57BL6 mice stained for
Proliferating Cell Nuclear Antigen (PCNA) (black arrows = example of positive cell, white arrows = example of
negative cells). Periosteum, dura and osteogenic front (OF) are as marked, and the sutural area has been
outlined. C. Quantification of percent PCNA stain. PCNA activity shows slight decreases for all but dural
associated areas, but no statistical differences. D & E. Sagittal sutures from control (D) and exposed (E) 15
day old C57BL6 mice stained for PCNA. F. Quantification of percent PCNA stain. Overall, PCNA activity
increased in all areas assessed in citalopram exposed sagittal sutures.
doi:10.1371/journal.pone.0139719.g001
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dose F = 7.515, p<0.001. Post-hoc Bonferonni analysis revealed media only treatment to result
in significantly less MTS activity compared with all treated groups respectively, p<0.05, with
the exception of 10−10 mol/liter. Fig 2B demonstrates qrt-PCR results for three markers of pro-
liferation (Ki67, Ccnd1, and Jun) after 3 and 7 days of citalopram treatment at 10−4 mol/liter on
MC3T3-E1 cells. Results suggest mean increases for all markers at both time points. After 7
days all three markers are found to have confidence intervals that do not cross 1 indicating pur-
ported biological change. Jun is found to be significantly different between treatment and con-
trol at both 3 and 7 days.
Markers of Apoptosis
Fig 3A, 3B, 3D and 3E demonstrates representative samples of Terminal deoxynucleotidyl tran-
ferase dUTP nick end labeling (TUNEL a method for detecting DNA fragmentation due to
apoptosis) staining for coronal and sagittal sutures from postnatal day 15 animals either unex-
posed (control) or exposed to citalopram in utero. Qualitative assessment suggests decreased
TUNEL staining for SSRI exposed coronal sutures. Sagittal sutures demonstrated very little
TUNEL activity. Quantitative analysis was conducted for percent cells TUNEL positive as a
function of total cells present. A three-way analysis of variance was conducted to determine if
the relationship for exposure (control or citalopram) by area of suture was the same for coronal
and sagittal suture samples. Assumptions of normality was met for all groups with the
Fig 2. Assessment of in vitromarkers of proliferation after citalopram treatment. A. MTS functional
assay results fromMC3T3 cells treated with serial dilutions of citalopram (10−4 mol through 10−10 mol).
Significant time and dose effects are noted. B. Gene expression markers of proliferation fromMC3T3 cells
treated with media only or media supplemented with 10−4 mol citalopram. All three markers indicate a
biological change due to treatment by 7 days. Junwas found to have significantly greater expression due to
treatment at both 3 and 7 days.
doi:10.1371/journal.pone.0139719.g002
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exception of osteogenic front coronal suture not exposed (control) and sagittal suture exposed
to citalopram. ANOVA is robust against this violation. The assumption of homogeneity of var-
iance was met. Results indicated a significant difference for suture by exposure interaction
term, F = 46.169, p<0.001 with TUNEL decreasing with exposure for the coronal suture and
the sagittal not changing or a slightly increasing. Two-way analyses of variance were conducted
for coronal and sagittal suture. The results for the coronal suture are illustrated in Fig 3C. Data
suggests decreases in markers of apoptosis in all areas analyzed. The assumption of homogene-
ity was met. Statistical analyses revealed significant differences for exposure F = 39.692,
p<0.001 with SSRI exposed sutures (4.74+/-2.87) having statistically less TUNEL activity than
control (14.90 +/- 7.76). There was also a significant difference by area F = 7.740, p = 0.02.
Post-hoc bonferonni analyses revealed the osteogenic front to have significantly less TUNEL
activity than the periosteal or dural area, p<0.05. The results for the sagittal suture are illus-
trated in Fig 2F. Data suggests very little TUNEL activity for the sagittal suture. The assump-
tion of homogeneity was met. Statistical analyses revealed significant differences for exposure
F = 6.617, p = 0.02 with SSRI exposed sutures (4.16+/-3.26) having statistically greater TUNEL
activity than control (2.19 +/- 1.72). There was also a significant difference by area F = 5.775,
p = 0.007. Post-hoc bonferonni analyses revealed the dural area to have significantly greater
TUNEL activity than the periosteal or osteogenic front areas, p<0.05.
Fig 4A demonstrates results for apoptosis via Capase 3/7 activity analysis of MC3T3-E1
cells after citalopram treatment in culture for 3 and 7 days. Qualitative assessment suggests
decreases in caspase activity for all treated groups compared to untreated baseline control. In
addition no caspase activity was detected for the 10−4 mol/liter after 7 days in culture. A two
way analysis of variance was conducted for days in culture by citalopram dose for Caspase
activity. Assumptions of normality and homogeneity of variance were met. Results suggest no
statistically significant differences in Caspase activity by day, dose or interaction terms. Fig 4B
Fig 3. Histological markers of apoptosis in control and citalopram exposedmouse cranial sutures. A
& B. Coronal sutures from control (A) and citalopram exposed (B) 15 day old C57BL6mice stained for
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) activity (green). Periosteum, dura
and osteogenic front (OF) are as marked, and the sutural area has been outlined. Inset lower magnification of
TUNEL staining with a 4',6-diamidino-2-phenylindole (DAPI) nuclear counterstain (blue). Note the highly
cellularized (blue stained) area of the suture abutting the less cellularized (darker) area of the osteogenic
front. C. Quantification of percent TUNEL positive staining as compared to DAPI stain in coronal sutures.
Significant decreases in TUNEL activity were noted due to citalopram exposure at the periosteal and dural
areas of the sutures. Midsutral space and osteogenic fronts did not demonstrate significantly different
staining between unexposed and citalopram exposed sutures. D & E. Sagittal sutures from unexposed
(control) (D) and citalopram exposed (E) 15 day old C57BL6 mice stained for TUNEL activity (green). Inset
lower magnification of TUNEL staining with a DAPI nuclear counterstain (blue) F. Quantification of percent
TUNEL positive staining as compared to DAPI stain. A significant increase in TUNEL staining was noted in
the periosteal area while a significant decrease in staining was noted at the osteogenic front of citalopram
exposed sagittal sutures.
doi:10.1371/journal.pone.0139719.g003
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demonstrates qrt-PCR results for three markers of apoptosis (Bax, Bcl2, and Casp3) after 3 and
7 days of citalopram treatment at 10−4 mol/liter on MC3T3-E1 cells. All markers had confi-
dence intervals crossing 1 and mean fold changes around 1 suggesting no biological changes.
Bax was slightly above 1 fold change suggesting slight increase for both time points and Casp3
and Bcl2 showed slight decreases for both time points. There were no statistically significant
gene expression changes.
Discussion
Here we set out to determine if exposure to SSRIs would alter the cell cycle (proliferation and
apoptosis) of perisutural cells at the cellular and transcription levels. Our previous data sug-
gested that there was some mechanism causing measurable growth alterations even when dos-
ages of SSRI were moderate to low. We sought to determine if there was a specific effect of
SSRI treatment on perisutural cell cycle regulation disrupting homeostasis [24]. For
Fig 4. Assessment of in vitromarkers of apoptosis after citalopram treatment. A. Caspase 3/7
functional assay results fromMC3T3 cells treated with serial dilutions of citalopram (10−4 mol through 10−10
mol). No significantly significant differences were found by day, dose, or interaction terms. B. Gene
expression markers of apoptosis fromMC3T3 cells treated with media only or media supplemented with 10−4
mol citalopram. There were no statistically significant gene expression changes.
doi:10.1371/journal.pone.0139719.g004
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proliferation measured in the sutural areas of mice exposed to the SSRI citalopram, there seems
to be little exposure related effect in the coronal suture, whereas there is a greater effect in the
sagittal suture due to exposure. The effect of increasing PCNA (a marker for proliferation) in
suture associated cells was confirmed with the increase in MTS activity in murine pre-osteo-
blast cells over time and dosage of SSRI. TUNEL staining for apoptotic activity indicated that
there was a relative decrease in apoptotic activity in coronal sutures exposed to SSRI as com-
pared to control and a similar result was shown for the sagittal suture with the exception of an
increase in apoptotic activity due to SSRI exposure recorded at the periosteal end of the suture.
Minimal changes in apoptotic activity of cells treated with citalopram and in apoptosis related
gene expression correlate with the very small changes demonstrated in the histomorphometric
analysis.
It appears that overall exposure to the SSRI citalopram has a greater effect on proliferation
and a lesser effect on apoptotic activity. Together these changes indicate that exposure to SSRIs
affects cell cycle regulation by increasing proliferative potential and decreasing apoptotic activ-
ity in a site specific manner that may be indicative of hyperplasia. By analyzing the proliferative
and apoptotic activity of control and citalopram exposed sutures we were able to identify site
specific cell cycle changes that may have been missed if the suture has been analyzed as a
whole. The decrease in TUNEL staining, indicating a decrease in apoptotic activity seen at the
dural edge of the coronal suture in conjunction with the small increase in PCNA staining indi-
cating an increase in proliferation in the same area may be indicative of hyperplasia. Likewise,
the increase in TUNEL staining at the periosteum associated edge of the sagittal suture in con-
junction with the increase in PCNA activity in that same area still results in a suture with rela-
tively more cells at the dural edge than the periosteal edge. Such greater cell division and
decreased programmed cell death may have specific implications for suture development.
Hyperplasia may likely result in hyperostosis at the suture possibly leading to obliteration and
synostosis. Research has indicated suture fusion often begins endocranially (near the dura)
[41]. This is significant as our data suggests a pattern with increased cell cycle dysregulation
near the dura which may lead to premature suture fusion.
Likewise, the assessment of genetic markers of cell cycle regulation and the balance between
proliferation and apoptosis point towards a situation of hyperplasia resulting from exposure to
SSRIs. The genetic markers of cell cycle progression were upregulated in suture associated cells
when exposed to citalopram. Increasing expression of Ki67, Ccnd1 and its regulating gene Jun
all indicate an increase in cell cycle progression due to exposure to SSRI. The initial increase in
Jun expression due to SSRI exposure is predictably followed by increased expression of Ccnd1
indicating more cells in the G1 phase of the cell cycle. This increase in proliferative activity due
to SSRI exposure is confirmed by an increase in Ki67 expression indicating that cells are pro-
gressing through all phases of the cell cycle [42, 43]. Together these genes indicate an increase
in cell cycling and thus proliferation. Additionally, upregulation of Jun is also indicative of
anti-apoptotic activity which may be balancing the lack of pro-survival gene Bcl2 expression
seen in the perisutural cells. Though there may be a slight decrease in expression of Bcl2 in
response to treatment with the SSRI citalopram there is no associated increase in expression of
Bax and therefore there is also no increase in expression of Casp3 to facilitate apoptotic activity
[42]. Thus, though there is no change in genes associated with apoptosis recorded here, the
increase in proliferation related gene expression observed is likely sufficient to cause an imbal-
ance in cell cycle regulation. Overall it seems as if there is a disruption in the balance of prolif-
erative and apoptotic activity that results from exposure to citalopram.
The tight coordination of cellular proliferation and differentiation are known to be impor-
tant for maintenance of the patent cranial suture and the eventual or pathological fusion.
These balances are often cited as being controlled by regulatory networks known to be involved
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in craniofacial growth and development, includingMSX, FGFs, TGFβs and TWIST genes [27–
31, 44–50]. We have previously shown that citalopram alters FGF, MSX and TGFB expression
in osteoblast cell culture [24]. In addition, several preclinical studies have also suggested apo-
ptosis to be necessary for the maintenance of the suture [25, 26]. Here we found that exposure
to the SSRI citalopram was able to significantly alter the balance of cell proliferation and differ-
entiation within the suture. Here these alterations were identified in a wild-type model not
genetically predisposed to craniofacial abnormalities such as craniosynostosis, as we would
predict in those with certain gene mutations citalopram exposure may exacerbate dysfunction.
As most cases of craniosynostosis are non-syndromic with no identified genetic mutation
efforts are now focusing on the association of potential mediators on calvarial growth and
development and synostosis [51, 52]. SSRI use (exposure to fetus through blood/placental bar-
rier) has been identified as having an elevated risk association for craniosynostosis [1, 2, 4, 5,
18, 19]. Evidence here suggests these drugs, even at low and variable dosages, may have a direct
effect on the homeostasis of cells within the calvaria and suture. Importantly, the differential
effect by area seen here could be indicative of cell type specific effects in the suture areas
defined by consisting of multiple cell types. A future assessment of the effect of citalopram
exposure on heterogeneous cell type primary cells derived from sutures would be appropriate.
Future research should expand on modeling these SSRIs for dose by time interaction to study
craniofacial growth and identify potential caustic doses or windows of susceptibility effects on
development.
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